info icon

This is a non-core endpoint: only basic statistics are computed.

See these related core endpoints for full statistics:

Carcinoma in situ of other and unspecified sites (controls excluding all cancers)

CD2_INSITU_OTHER_NOS_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector

Check conditions None

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D09
Cause of death: ICD-10 D09

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

734

diagram downward connector
CD2_INSITU_OTHER_NOS_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF2
Parent code in ICD-10 D00-D09
Name in latin Carcinoma in situ locis aliis sive non specificatis

Similar endpoints

List of similar endpoints to Carcinoma in situ of other and unspecified sites (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 734 144 590
Unadjusted prevalence (%) 0.19 0.07 0.35
Mean age at first event (years) 70.00 65.83 71.02

Mortality

Not a core endpoint, no data to show.

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Not a core endpoint, no data to show.

Correlations

Index endpoint: CD2_INSITU_OTHER_NOS_EXALLC – Carcinoma in situ of other and unspecified sites (controls excluding all cancers)
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Carcinoma in situ of other and unspecified sites (controls excluding all cancers)

Endpoint not on priority list, no data to show.